NanoString Technologies partner with Cell Signaling Technology


Massachusetts, March 10, 2016 — NanoString Technologies, Inc. and Cell Signaling Technology (CST) have reached an accord to use highly validated antibodies from CST in NanoString’s 3D Biology Protein Profiling Panels. 3D Biology applications allow researchers to concurrently measure combinations of up to 800 DNA, RNA and protein targets in a singular experiment.

The agreement brings together leaders in the fields of multiplexed genomic profiling and antibody development to create new protein-based assays that will expand NanoString’s 3D Biology product offerings. Under the agreement, CST will supply antibodies for use in NanoString assays which will be marketed by NanoString for use with its nCounter® Analysis System. These assays will provide investigators with powerful tools to uncover the molecular mechanisms of disease and enable the development of more comprehensive treatment strategies.

“Multiplexed analysis of gene and protein expression has the potential to improve the way we diagnose and treat patients with cancer. This agreement is aligned with our platform content enablement initiatives. By working with NanoString, we expect to further the advancement of new biomarkers and better targeted therapies,” said Roberto Polakiewicz, Chief Scientific Officer of CST.

“We are pleased to bring CST’s highly validated antibodies into our nCounter 3D Biology platform to give customers a wide array of protein targets to choose from. High quality CST antibodies should enable us to build on our reputation for precise and reproducible data. Our customers will benefit from multiplexed, single molecule, digital quantification of proteins with a rapidly expanding menu of assays,” added Joseph Beechem, Senior Vice President of Research and Development at NanoString.

About NanoString Technologies, Inc.

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company’s nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company’s technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.


scroll to top